About: Giovanni Sotgiu

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Giovanni Sotgiu Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher (ORCID 0000-0002-1600-4474)

Attributes	Values
rdf:type	Item
description	연구원 (ko) গবেষক (bn) 研究者 (ja) ഗവേഷകൻ (ml) wetenschapper (nl) дослідник (uk) эрдэмтэн (mn) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) hulumtues (sq) researcher (ORCID 0000-0002-1600-4474) (en)
rdfs:label	Giovanni Sotgiu (en) Giovanni Sotgiu (es) Giovanni Sotgiu (it) Giovanni Sotgiu (nl) Giovanni Sotgiu (sl) Giovanni Sotgiu (ast)
skos:prefLabel	Giovanni Sotgiu (en) Giovanni Sotgiu (es) Giovanni Sotgiu (it) Giovanni Sotgiu (nl) Giovanni Sotgiu (sl) Giovanni Sotgiu (ast)
name	Giovanni Sotgiu (en) Giovanni Sotgiu (es) Giovanni Sotgiu (it) Giovanni Sotgiu (nl) Giovanni Sotgiu (sl) Giovanni Sotgiu (ast)
Scopus author ID	wds:Q41436294-675CDCE4-22D4-41C2-82F3-4EC96364B32C
Scopus author ID	55541541000
given name	wds:Q41436294-2A1BB47E-682F-4286-A92E-571990B552D8
given name	Giovanni
instance of	wds:Q41436294-5E618134-FB07-46A3-8337-BDF758E12A7F
instance of	Homo sapiens
occupation	wds:Q41436294-952CA1B8-B2CF-4464-9D48-7D7F75D21672
sex or gender	wds:Q41436294-FF4A6BCB-6975-42F0-9FFC-C512EEB526E5
on focus list of Wikimedia project	wds:Q41436294-971B10CB-6FB5-4B55-83CF-00F7040A586C
family name	wds:Q41436294-443A9787-83A6-42D3-B249-BE2EC610612D
occupation	researcher
sex or gender	male
on focus list of Wikimedia project	WikiProject COVID-19
family name	Sotgiu
ORCID iD	wds:Q41436294-E1CE1F34-DD60-46DF-A151-9D38C6A03CF6
ORCID iD	https://orcid.org/0000-0002-1600-4474
ORCID iD	0000-0002-1600-4474
IRIS UNIPV author ID	wds:Q41436294-CE17DCE7-64C8-42C8-8D2A-FE9A7918BCA5
IRIS UNIPV author ID	185493
ResearcherID	wds:Q41436294-6FF3A8B4-1874-4A76-9803-991F6CA93718
Publons author ID	wds:Q41436294-b6940b43-2205-49aa-88ba-dbefbedf6253
ResearcherID	N-1032-2017
Publons author ID	1288495
Mendeley person ID	wds:Q41436294-FA2AC919-1C76-4EBD-AC35-DBA17D5D5533
Mendeley person ID	giovanni-sotgiu3
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q41436294
is author of	Interferon- release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis Distribution of the CCR5 Delta32 Allele in Italian HIV Type 1-Infected and Normal Individuals Longitudinal study of two cases of progressive multifocal leukoencephalopathy with a clinical benign evolution. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. European union standards for tuberculosis care Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). Availability of anti-tuberculosis drugs in Europe: Table 1– TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel? Defining priorities: swine-origin H1N1 and the MDR-TB epidemic Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection Potential role for IL-2 ELISpot in differentiating recent and remote infection in tuberculosis contact tracing Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study Identifying predictors of interferon-γ release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Latent tuberculosis infection and associated risk factors among undergraduate healthcare students in Italy: a cross-sectional study Towards tuberculosis elimination: an action framework for low-incidence countries Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster On linezolid efficacy and tolerability Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays. A Tuberculosis Network European Trials Group Study. Update in tuberculosis and nontuberculous mycobacterial disease 2010. Tuberculosis elimination: theory and practice in Europe Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia Multidrug- and extensively drug-resistant tuberculosis, Germany Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Tuberculosis treatment and drug regimens Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 182 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software